145020 - Hugel, Inc.

145020 Summary

Biopharma

Stock Price & Overview

₩244,000 +3,500 (+1.46%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩244,000 ≈ US$174 · Market cap ₩3.1tn (≈ $2.2bn)

145020 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	425.1	373.0	319.7	281.7	231.9	211.0	204.6	182.4	182.1	124.2	65.1
Cost of Revenue	91.6	85.9	73.5	62.8	54.8	62.3	60.6	51.0	40.0	29.8	26.6
Gross Profit	333.5	287.2	246.2	218.9	177.1	148.8	143.9	131.4	142.1	94.4	38.5
Selling, General & Administrative	132.6	120.9	128.4	117.5	81.5	70.7	75.9	71.2	40.2	31.1	20.7
Operating Income	200.9	166.2	117.8	101.4	95.6	78.1	68.1	60.2	101.9	63.3	17.8
Finance Income	17.5	25.2	42.0	22.6	12.0	26.7	15.9	18.8	5.9	2.0	1.0
Finance Costs	9.5	4.7	14.8	44.5	20.0	27.9	12.1	3.7	2.2	0.5	0.3
Pretax Income	196.8	165.2	133.3	73.1	87.4	69.3	69.7	99.5	103.5	64.3	39.3
Income Tax Expense	49.8	22.0	35.6	9.2	28.3	24.0	19.4	23.9	22.2	13.4	3.5
Net Income	147.0	143.1	97.7	60.7	60.4	45.3	50.3	75.7	81.4	50.9	35.9
Total Comprehensive Income	150.1	160.8	97.9	63.4	69.8	48.9	47.0	72.8	81.2	—	—

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	1.08	0.94	0.93	1.05	1.01	0.96	0.89	0.92	0.82	0.29	0.23
Current Assets	0.68	0.52	0.57	0.62	0.62	0.67	0.64	0.68	0.68	0.15	0.11
Cash & Cash Equivalents	0.21	0.13	0.11	0.13	0.29	0.06	0.02	0.03	0.03	0.06	0.07
Inventories	0.06	0.04	0.03	0.03	0.03	0.02	0.03	0.02	0.02	0.01	0.01
Trade Receivables	0.07	0.05	0.04	0.05	0.03	0.03	0.04	0.06	0.06	0.03	0.02
Non-current Assets	0.40	0.42	0.36	0.43	0.39	0.29	0.25	0.23	0.14	0.14	0.13
Property, Plant & Equipment	0.15	0.15	0.13	0.12	0.10	0.08	0.07	0.06	0.06	0.06	0.05
Intangible Assets	0.19	0.20	0.18	0.20	0.20	0.17	0.13	0.11	0.06	0.06	0.06
Total Liabilities	0.10	0.10	0.15	0.20	0.18	0.16	0.15	0.13	0.10	0.02	0.02
Current Liabilities	0.09	0.06	0.06	0.18	0.05	0.04	0.04	0.02	0.02	0.02	0.02
Non-current Liabilities	0.00	0.04	0.09	0.02	0.13	0.12	0.11	0.11	0.08	0.00	0.00
Total Equity	0.98	0.84	0.78	0.85	0.83	0.79	0.74	0.78	0.72	0.27	0.22
Share Capital	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.00
Retained Earnings	1.16	1.07	0.94	0.90	0.84	0.81	0.77	0.76	0.18	0.11	0.06

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	150.1	149.1	117.7	80.6	85.9	74.3	77.0	65.8	64.2	45.1	19.8
Cash from Investing Activities	-48.7	42.4	43.2	-191.8	180.1	-25.3	-1.0	-32.2	-555.3	-53.9	-17.1
Purchase of Property, Plant & Equipment	13.4	12.4	23.7	32.8	23.9	17.0	12.3	9.1	6.3	15.6	12.4
Cash from Financing Activities	-21.7	-172.1	-187.1	-51.4	-36.0	-1.8	-90.3	-35.6	457.6	3.1	50.4
Dividends Paid	0.0	0.0	0.1	—	—	—	—	—	—	—	—
Net Change in Cash	79.6	19.4	-26.2	-162.6	230.0	47.2	-14.3	-2.0	-33.6	-5.6	53.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	137.9	116.6	119.1	105.9	110.3	89.8	98.2	105.1	95.4	74.3
Cost of Revenue	32.1	26.6	23.0	24.2	23.6	20.8	22.5	22.2	23.9	17.2
Gross Profit	105.8	90.1	96.2	81.7	86.6	69.0	75.7	82.9	71.5	57.1
Selling, General & Administrative	49.7	42.5	38.4	34.3	30.0	30.1	29.3	29.5	29.1	33.1
Operating Income	56.0	47.6	57.8	47.4	56.7	39.0	46.5	53.4	42.4	24.0
Finance Income	4.9	10.4	5.1	4.7	3.2	4.5	9.8	2.2	6.8	6.4
Finance Costs	-0.0	1.3	3.1	0.6	4.1	1.8	1.3	1.3	1.2	0.9
Pretax Income	61.4	56.1	51.3	51.1	53.3	41.1	35.3	53.0	47.5	29.4
Income Tax Expense	16.7	15.5	11.5	13.1	15.0	10.2	-6.1	11.0	10.5	6.7
Net Income	44.7	40.6	39.8	38.0	38.2	30.9	41.4	42.0	37.0	22.7
Total Comprehensive Income	48.1	49.7	41.5	44.7	27.0	37.0	55.4	38.2	38.7	28.5

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	1.19	1.13	1.08	1.03	1.01	0.97	0.94	0.94	0.90	0.92
Current Assets	0.76	0.72	0.68	0.62	0.60	0.56	0.52	0.55	0.50	0.53
Cash & Cash Equivalents	0.26	0.25	0.21	0.17	0.18	0.16	0.13	0.18	0.15	0.15
Inventories	0.06	0.06	0.06	0.05	0.05	0.04	0.04	0.04	0.04	0.04
Trade Receivables	0.09	0.07	0.07	0.08	0.06	0.04	0.05	0.04	0.04	0.03
Non-current Assets	0.43	0.41	0.40	0.41	0.41	0.41	0.42	0.39	0.40	0.39
Property, Plant & Equipment	0.17	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15	0.15
Intangible Assets	0.20	0.20	0.19	0.20	0.19	0.20	0.20	0.19	0.19	0.19
Total Liabilities	0.10	0.10	0.10	0.10	0.12	0.09	0.10	0.09	0.09	0.16
Current Liabilities	0.10	0.10	0.09	0.08	0.08	0.06	0.06	0.05	0.05	0.06
Non-current Liabilities	0.00	0.00	0.00	0.01	0.04	0.04	0.04	0.04	0.04	0.10
Total Equity	1.09	1.03	0.98	0.93	0.89	0.88	0.84	0.85	0.81	0.75
Share Capital	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Retained Earnings	1.24	1.20	1.16	1.12	1.09	1.10	1.07	1.03	0.99	0.96

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	40.9	57.4	64.7	18.4	26.3	40.6	46.5	46.8	19.8	35.9
Cash from Investing Activities	-28.0	-20.6	-24.9	-8.3	-10.3	-5.2	-36.7	-13.7	29.7	63.1
Purchase of Property, Plant & Equipment	14.5	11.5	4.7	2.4	2.6	3.6	2.6	3.6	4.2	2.0
Cash from Financing Activities	-0.8	-0.8	-0.3	-23.9	4.1	-1.7	-66.9	-0.0	-50.5	-54.7
Net Change in Cash	12.1	36.0	39.6	-13.8	20.2	33.7	-57.2	33.1	-0.9	44.3

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

145020 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	425.1	+14.0%	+14.7%	+15.0%	+20.6%
Operating income	200.9	+20.8%	+25.6%	+20.8%	+27.5%
Net income	147.0	+2.7%	+34.3%	+26.5%	+15.2%
EPS	₩11,744	+2.7%	+34.3%	+26.5%	+15.2%
Operating cash flow	150.1	+0.7%	+23.0%	+15.1%	+22.5%
Shareholders' equity	980.2	+16.6%	+4.9%	+4.3%	+16.4%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

145020 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	78.4%	77.0%	77.0%	77.7%	76.4%	70.5%
Operating margin	47.2%	44.6%	36.8%	36.0%	41.2%	37.0%
Net margin	34.6%	38.4%	30.5%	21.5%	26.0%	21.5%
Return on equity	16.1%	17.7%	12.0%	7.2%	7.4%	5.9%
Return on assets	14.6%	15.3%	9.9%	5.9%	6.1%	4.9%
Operating cash flow / revenue	35.3%	40.0%	36.8%	28.6%	37.1%	35.2%
Capex / revenue	3.2%	3.3%	7.4%	11.7%	10.3%	8.0%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 145020

Symbol	Last Price
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.